Table 2.
Characteristics of patients and healthy individuals.
| Diagn. | No. | Age | Sex | Subtype | Stage | Ic bla | Blast Phenotype [cd] | Risk Class. | Response | Exp. |
|---|---|---|---|---|---|---|---|---|---|---|
| AML | 1444 | 35 | f | p/M1 | dgn. | 41 | 33, 65, 15, 34, 117 | favorable | yes | DC; MLC; CTX |
| AML | 1540 | 83 | f | p/M1 | dgn. | 32 | 13, 34, 33, 15, 117, 56 | favorable | no | DC; MLC; CTX; D/I |
| AML | 1427 | 52 | m | p/M2 | dgn. | 94 | 13, 33, 34, 117 | favorable | no | DC; MLC; CTX |
| AML | 1541 | 82 | f | p/M2 | dgn. | 15 | 15, 34, 117 | interm. | no | DC; MLC; CTX; D/I |
| AML | 1442 | 73 | f | p/M4 | dgn. | 15 | 33, 13, 34, 117, 15 | interm. | yes | DC; MLC; CTX |
| AML | 1459 | 54 | m | p/M4 | dgn. | 51 | 33, 64, 15, 4, 56, 14 | favorable | yes | DC; MLC; CTX |
| AML | 1430 | 79 | m | p/M5 | dgn. | 62 | 13, 33, 34, 117 | favorable | nd | DC; MLC; CTX |
| AML | 1432 | 34 | m | p/M5 | dgn. | 57 | 34, 13, 33, 64, 4 | interm. | yes | DC; MLC; CTX |
| AML | 1466 | 47 | f | p/M5 | dgn. | 11 | 33, 15, 13, 117, 34 | adverse | yes | DC; MLC; CTX |
| AML | 1575 | 62 | f | p/M5a | dgn. | 75 | 14, 56, 64, 65, 4 | interm. | yes | DC; MLC; CTX; D/I |
| AML | 1452 | 44 | m | p/nd | dgn. | 11 | 34, 117, 33, 13 | interm. | no | DC; MLC; CTX |
| AML | 1568 | 29 | m | p/nd | dgn. | 69 | 34, 117, 33, 13, 19, 20, 65 | interm. | no | DC; MLC; CTX; D/I |
| AML | 1570 | 36 | f | p/nd | dgn. | 11 | 34, 117, 65, 13, 33 | favorable | no | DC; MLC; CTX; D/I |
| AML | 1492 | 52 | f | s/M2 | dgn. | 38 | 117, 34, 13, 33, 7, 15 | nd | no | DC; MLC; CTX |
| AML | 1542 | 58 | f | s/M4 | dgn. | 52 | 13, 33, 34, 117, 15, 65, 64, 2, 56, 14 | adverse | no | DC; MLC; CTX; D/I |
| AML | 1426 | 61 | f | s/M5 | dgn. | 34 | 13, 33, 34, 64, 117, 14 | adverse | yes | DC; MLC; CTX |
| AML | 1464 | 72 | m | s/nd | dgn. | 38 | 34, 117, 13 | nd | nd | DC; MLC; CTX |
| AML | 1555 | 46 | f | s/nd | dgn. | 20 | 33, 14, 15, 117, 13 | favorable | nd | DC; MLC; D/I |
| AML | 1574 | 56 | m | s/nd | dgn. | 41 | 34, 117, 15, 19 | nd | no | DC; MLC; CTX; D/I |
| AML | 1571 | 61 | m | p/M2 | rel. | 18 | 117, 33, 13, 7 | nd | yes | DC; MLC; CTX; D/I |
| AML | 1424 | 37 | f | p/M4 | rel. | 13 | 13, 14, 33, 117 | nd | nd | DC; MLC; CTX |
| AML | 1548 | 87 | m | p/M5a | rel. | 12 | 33, 15, 117, 34, 56 | nd | no | DC; MLC; CTX; D/I |
| AML | 1449 | 78 | m | s/nd | rel. | 32 | 65, 14, 15, 33, 56, 34 | nd | nd | DC; MLC; CTX |
| AML | 1482 | 75 | m | s/nd | rel. | 12 | 117, 13, 64, 15, 117, 33 | nd | nd | DC; MLC; CTX |
| AML | 1546 | 80 | m | p/nd | pers. | 22 | 33, 34, 13, 117, 14, 65 | nd | no | DC; MLC; |
| AML | 1470 | 67 | m | p/nd | PR a. SCT | 38 | 33, 117, 34, 56, 65 | nd | no | DC; MLC |
| AML | 1457 | 63 | m | s/nd | rel. a. SCT | 37 | 34, 117, 13, 65, 15 | nd | no | DC; MLC; CTX |
| AML | 1543 | 61 | m | p/nd | rel. a. SCT. | 38 | 13, 33, 117, 56, 34 | nd | no | DC; MLC; CTX |
| MDS | 1567 | 98 | f | MDS | dgn. | 14 | 34, 117, 15, 65, 56, 14 | very high | nd | DC; MLC; CTX; D/I |
| MDS | 1573 | 61 | m | MDS | dgn. | 12 | 34, 117, 65, 13, 61 | high | no | DC; MLC; CTX; D/I |
| MDS | 1572 | 63 | f | MDS-EB2 | dgn. | 10 | 34, 117, 65, 33, 13 | very high | no | DC; MLC; CTX; D/I |
| healthy | 1417 | 34 | f | DC; MLC | ||||||
| healthy | 1418 | 22 | m | DC; MLC | ||||||
| healthy | 1421 | 27 | f | DC; MLC | ||||||
| healthy | 1422 | 20 | f | DC; MLC | ||||||
| healthy | 1425 | 27 | m | DC; MLC | ||||||
| healthy | 1428 | 56 | f | DC; MLC | ||||||
| healthy | 1429 | 22 | f | DC; MLC | ||||||
| healthy | 1431 | 22 | m | DC; MLC | ||||||
| healthy | 1436 | 25 | m | DC; MLC | ||||||
| healthy | 1440 | 20 | f | DC; MLC | ||||||
| healthy | 1448 | 27 | f | DC; MLC | ||||||
| healthy | 1458 | 21 | f | DC; MLC | ||||||
| healthy | 1544 | 22 | m | DC; MLC; D/I | ||||||
| healthy | 1545 | 32 | m | DC; MLC; D/I | ||||||
| healthy | 1547 | 46 | f | DC; MLC; D/I | ||||||
| healthy | 1566 | 54 | f | DC; MLC; D/I | ||||||
| healthy | 1576 | 55 | m | DC; MLC; D/I | ||||||
| healthy | 1578 | 32 | m | DC; MLC |
Diagn.—diagnosis; No.—sample number; m—male; f—female. Subtypes: p—primary AML; s—secondary AML. AML (FAB classification); MDS (WHO classification); rel. a. SCT—relapse after stem cell transplantation; rel.—relapse; dgn.—first diagnosis; pers.—persisting disease; PR—partial remission; nd—no data; Ic Bla—immunocytologically determined blasts; Risk Class: cytogenetic (AML ELN) and multifactorial (MDS IPSS-R) risk classification; Response—response to (induction) chemotherapy; Exp.—conducted experiments; MLC—mixed lymphocyte culture; DC—dendritic cell generation; CTX—cytotoxic fluorolysis assay; D/I—degranulation and intracellular cytokine assay.